Vepdegestrant

– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio Breast Cancer Symposium in December 2024 – – Recently presented new preclinical data for the PROTAC LRRK2 degrader ARV-102 demonstrating that LRRK2 degradation affects biomarkers in the CSF – - $1.1 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2024 - – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We maintained strong momentum across our portfolio in the third quarter and remain on track to report topline data from VERITAC-2, our Phase 3 clinical trial in metastatic breast cancer, in the fourth quarter of 2024 or the first quarter of 2025,” said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. “In partnership with our colleagues at Pfizer, we are excited by the possibility of changing the treatment paradigm for ER+/HER2- breast cancer and look forward to sharing results from VERITAC-2 in the coming months.” “Our path to reaching our goal of becoming a multi-product, commercial-stage organization with a robust pipeline across several indications is clearly defined, and our novel PROTAC platform technology has the potential to enable opportunities across multiple therapeutic areas,” continued Dr. Houston. “We look forward to completing the multiple ascending dose portion of our Phase 1 clinical trial with ARV-102, our first PROTAC degrader with the potential to treat neurodegenerative diseases, and sharing data in 2025. We are also encouraged by the preclinical profile of ARV-393, our BCL6 PROTAC degrader currently being evaluated in a first-in-human Phase 1 clinical trial in patients with B-cell lymphomas. We look forward to sharing more about these programs in the coming months.” 3Q 2024 Business Highlights and Recent Developments Vepdegestrant Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer. VERITAC-2: Phase 3 monotherapy clinical trial in patients with metastatic breast cancer (ClinicalTrials.gov Identifier: NCT05654623)TACTIVE-U: Phase 1b/2 combination umbrella trial evaluating combinations of vepdegestrant with abemaciclib, ribociclib, or samuraciclib (ClinicalTrials.gov Identifiers: NCT05548127, NCT05573555, and NCT06125522).TACTIVE-K: Phase 1/2 clinical trial with vepdegestrant plus Pfizer’s novel CDK4 inhibitor atirmociclib (ClinicalTrials.gov Identifier: NCT06206837) ARV-102: Oral PROTAC LRRK2 degrader In October, presented preclinical data at the 2024 Michael J. Fox Foundation Parkinson’s Disease Conference further supporting the potential of PROTAC-induced leucine-rich repeat kinase 2 (LRRK2) degradation as a potential treatment for patients with neurodegenerative diseases. New findings presented included data demonstrating: Orally delivered ARV-102 crosses the blood-brain barriers and degrades LRRK2 in the cerebrospinal fluid (CSF) of non-human primates (NHPs).Degradation of LRRK2 by ARV-102 induces changes in pathway (lysosomal and inflammation) biomarkers in the CSF of NHPs, which has not previously been demonstrated by kinase inhibitors of LRRK2.In murine tauopathy models, oral PROTAC LRRK2 degrader treatment led to ~50% pathologic tau reduction. Initiated the multiple ascending dose portion of the ongoing Phase 1 clinical trial in healthy volunteers. ARV-393: Oral PROTAC BCL6 degrader Continued recruiting patients in the first-in-human Phase 1 clinical trial in patients with B-cell lymphomas. Anticipated Upcoming Milestones and Expectations Vepdegestrant As part of Arvinas global collaboration with Pfizer, the companies plan to: Complete enrollment (4Q24) and announce topline data (4Q24/1Q25) for the VERITAC-2 Phase 3 monotherapy clinical trial in patients with metastatic breast cancer.Present initial safety and pharmacokinetic data from the TACTIVE-U sub-study (NCT05548127) of abemaciclib in combination with vepdegestrant at the San Antonio Breast Cancer Symposium (SABCS) in December 2024.Present data from the Phase 1 healthy volunteer pharmacokinetic trial of vepdegestrant in combination with midazolam to assess potential for drug-drug interaction at SABCS in December 2024 (NCT06256510).Continue enrollment of the ongoing Phase 1b/2 combination umbrella trial evaluating combinations of vepdegestrant with abemaciclib, ribociclib, or samuraciclib (TACTIVE-U; ClinicalTrials.gov Identifiers: NCT05548127, NCT05573555, and NCT06125522).Evaluate data from the study lead-in of the VERITAC-3 Phase 3 trial (NCT05909397) in patients with ER+/HER2- locally advanced or metastatic breast cancer (2H24).Continue enrollment and evaluate preliminary data from the ongoing clinical trial with vepdegestrant plus Pfizer’s novel CDK4 inhibitor atirmociclib (TACTIVE-K).Start Phase 3 combination trials in the first- and second-line settings (anticipated in 2025; pending emerging data and regulatory feedback). First-line setting with vepdegestrant plus atirmociclib or palbociclib.Second-line setting with vepdegestrant plus palbociclib and/or another CDK4/6 inhibitor. ARV-102: Oral PROTAC LRRK2 degrader Complete enrollment in the ongoing multiple ascending dose portion of a Phase 1 trial evaluating ARV-102 in healthy volunteersPresent data from the Phase 1 trial in 2025. ARV-393: Oral PROTAC BCL6 degrader Continue recruiting patients in the first-in-human Phase 1 clinical trial evaluating ARV-393 in patients with B-cell lymphomas. Novel PROTAC KRAS G12D degrader File an Investigational New Drug (IND) application in 2025. Financial GuidanceBased on its current operating plan, Arvinas believes its cash, cash equivalents, and marketable securities as of September 30, 2024, is sufficient to fund planned operating expenses and capital expenditure requirements into 2027. Third Quarter Financial Results Cash, Cash Equivalents, and Marketable Securities Position: As of September 30, 2024, cash, cash equivalents and marketable securities were $1,121.6 million as compared with cash, cash equivalents, restricted cash and marketable securities of $1,266.5 million as of December 31, 2023. The decrease in cash, cash equivalents and marketable securities of $144.9 million for the nine months ended September 30, 2024 was primarily related to cash used in operations of $158.1 million (net of $150.0 million received from the Novartis agreements), inclusive of a one-time cash termination fee in the amount of $41.5 million related to the termination of our laboratory and office space lease with 101 College Street LLC in August 2024 and the purchase of lab equipment and leasehold improvements of $1.5 million, partially offset by proceeds from the exercise of stock options of $7.7 million and unrealized gains on marketable securities of $7.2 million. Research and Development Expenses: Research and development expenses were $86.9 million for the quarter ended September 30, 2024, as compared with $85.9 million for the quarter ended September 30, 2023. The increase in research and development expenses of $1.0 million for the quarter was primarily due to an increase in compensation and related personnel expenses of $2.8 million, which are not allocated by program, partially offset by a decrease in external expenses of $2.2 million. External expenses include program-specific expenses, which decreased by $1.1 million, primarily driven by decreases in our ARV-766 and ARV-110 programs of $3.8 million and $1.6 million, respectively, partially offset by increases in our ARV-102 and ARV-393 programs of $2.5 million and $1.4 million, respectively, and our non-program specific expenses, which decreased by $1.1 million. General and Administrative Expenses: General and administrative expenses were $75.8 million for the quarter ended September 30, 2024, as compared with $22.6 million for the quarter ended September 30, 2023. The increase in general and administrative expenses of $53.2 million for the quarter was primarily due to a loss on the termination of our laboratory and office space lease with 101 College Street LLC of $43.4 million as well as increases in personnel and infrastructure related costs of $5.0 million, professional fees of $3.4 million and in developing our commercial operations of $1.2 million. Revenue: Revenue was $102.4 million for the quarter ended September 30, 2024 as compared with $34.6 million for the quarter ended September 30, 2023. Revenue for the quarter is related to the license agreement with Novartis, the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer, the collaboration and license agreement with Bayer and the collaboration and license agreement with Pfizer. The increase in revenue of $67.8 million was primarily due to revenue from the Novartis license agreement of $76.7 million, offset by a decrease in revenue from the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer of $7.6 million related to timing differences in clinical trials and program expenses and a decrease in revenue from Bayer of $1.1 million related to the termination of the Bayer Collaboration Agreement in August 2024. Investor Call & Webcast Details Arvinas will host a conference call and webcast today, October 30, 2024, at 8:00 a.m. ET to review its third quarter 2024 financial results and discuss recent corporate updates. Participants are invited to listen by going to the Events and Presentation section under the Investors page on the Arvinas website at www.arvinas.com. A replay of the webcast will be available on the Arvinas website following the completion of the event and will be archived for up to 30 days. About VepdegestrantVepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER positive (ER+)/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. About ArvinasArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the expected timing in connection with the completion of enrollment and reporting of topline data from the VERITAC-2 clinical trial; the potential to change the treatment paradigm for ER+/HER2- breast cancer; the goal of becoming a multi-product, commercial-stage organization with a robust pipeline across several indications; novel PROTAC platform technology having the potential to enable opportunities across multiple therapeutic areas; plans to present initial safety and pharmacokinetic data from the TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant at SABCS; plans to present data from the Phase 1 healthy volunteer pharmacokinetic trial of vepdegestrant in combination with midazolam at SABCS; plans to continue enrollment in the TACTIVE-U study and evaluate data from the study lead-in of the VERITAC-3 Phase 3 clinical trial; plans to continue enrollment and evaluate preliminary data from the TACTIVE-K clinical trial; the expected timing of initiation of Phase 3 vepdegestrant combination trials in the first- and second-line settings, pending emerging data and regulatory feedback; expected timing of filing an investigational new drug application for a KRAS G12D degrader; plans to compete enrollment in the multiple ascending dose portion of the ARV-102 Phase 1 clinical trial, the timing of the presentation of data from such clinical trial, and the timing of sharing additional information about the program; plans to continue recruiting patients in the Phase 1 ARV-393 clinical trial and timing of sharing additional information about the program; and statements regarding Arvinas’ cash, cash equivalents and marketable securities. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: Arvinas’ and Pfizer’s performance of the respective obligations with respect to Arvinas’ collaboration with Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant; whether Arvinas will be able to successfully conduct and complete development for its other product candidates, including whether Arvinas initiates and completes clinical trials for its product candidates and receives results from its clinical trials and preclinical studies on its expected timelines or at all; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas’ ability to protect its intellectual property portfolio; whether Arvinas’ cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release. ContactsInvestors:Jeff Boyle+1 (347) 247-5089Jeff.Boyle@arvinas.com Media:Kirsten Owens+1 (203) 584-0307Kirsten.Owens@arvinas.com Arvinas, Inc.Condensed Consolidated Balance Sheets (Unaudited) (dollars and shares in millions, except per share amounts)September 30, 2024December 31,2023Assets Current assets: Cash and cash equivalents$85.2 $311.7 Restricted cash — 5.5 Marketable securities 1,036.4 949.3 Accounts receivable 7.3 — Other receivables 7.5 7.2 Prepaid expenses and other current assets 13.1 6.5 Total current assets 1,149.5 1,280.2 Property, equipment and leasehold improvements, net 6.8 11.5 Operating lease right of use assets 1.0 2.5 Collaboration contract asset and other assets 9.8 10.4 Total assets$1,167.1 $1,304.6 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued liabilities$75.9 $92.2 Deferred revenue 199.2 163.0 Current portion of operating lease liabilities 0.8 1.9 Total current liabilities 275.9 257.1 Deferred revenue 304.5 386.2 Long-term debt 0.6 0.8 Operating lease liabilities 0.1 0.5 Total liabilities 581.1 644.6 Stockholders’ equity: Preferred stock, $0.001 par value, zero shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively — — Common stock, $0.001 par value; 68.7 and 68.0 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 0.1 0.1 Accumulated deficit (1,486.5) (1,332.7)Additional paid-in capital 2,068.3 1,995.7 Accumulated other comprehensive income (loss) 4.1 (3.1)Total stockholders’ equity 586.0 660.0 Total liabilities and stockholders’ equity$1,167.1 $1,304.6 Arvinas, Inc.Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended September 30,Nine Months Ended September 30,(dollars and shares in millions, except per share amounts) 2024 2023 2024 2023 Revenue$102.4 $34.6 $204.2 $121.6 Operating expenses: Research and development 86.9 85.9 264.9 284.5 General and administrative 75.8 22.6 131.3 73.3 Total operating expenses 162.7 108.5 396.2 357.8 Loss from operations (60.3) (73.9) (192.0) (236.2)Interest and other income, net 11.7 10.0 39.2 25.5 Net loss before income taxes and loss from equity method investment (48.6) (63.9) (152.8) (210.7)Income tax (expense) benefit (0.6) — (1.0) 0.7 Loss from equity method investment — (0.1) — (2.5)Net loss$(49.2)$(64.0)$(153.8)$(212.5)Net loss per common share, basic and diluted$(0.68)$(1.18)$(2.14)$(3.97)Weighted average common shares outstanding, basic and diluted 72.1 54.1 71.9 53.6

▎药明康德内容团队编辑 1998年，耶鲁大学的Craig Crews教授与加州理工学院的Ray Deschaies教授意外结识——一场学术会议的组织方恰好将两人的座位排在了一块。即兴交谈中，一个关于蛋白降解疗法的构想在二人脑海中逐渐成型。这次奇妙的相遇埋下了希望的种子并茁壮成长，多年后，蛋白降解疗法在学术界和产业界掀起热潮，迎来了井喷式发展时代。Craig Crews教授创立的两家公司备受市场青睐，开发蛋白降解靶向嵌合体（PROTAC）的Arvinas公司在2021年与辉瑞达成20亿美元合作，又在2024年4月与诺华达成超10亿美元合作；聚焦新一代降解技术调节诱导接近靶向嵌合体（RIPTAC）的Halda Therapeutics公司则在2024年8月刚刚完成1.26亿美元的B轮扩展融资。 作为全球支持蛋白降解疗法研发的重要赋能平台之一，药明康德也一路见证了两家“明星”公司从萌芽、成长，到如今的快速发展。在近期药明康德举办的投资者日期间，药明康德联席首席执行官杨青博士提到了这些成就背后的创业和合作故事。公开信息显示，早在2016年，药明康德在蛋白降解疗法开发尚在起步阶段时就建设了相应能力，是全球最早赋能PROTAC和RIPTAC类药物研发的公司之一。作为Arvinas和Halda Therapeutics的合作伙伴[参考资料1~2]，药明康德在多个环节深度赋能两家公司的新药研发，助力一流基础科学发现转化为创新疗法。 一场思维火花的碰撞，攻克“难以成药”靶点 两家公司取得当下的成功并非偶然。在创立公司之前，Craig Crews教授就已深耕蛋白质调控研究多年，他试图利用细胞内天然的“回收系统”，也就是“泛素介导的蛋白降解系统”构建抗癌疗法。时间回到1998年，Craig Crews教授与Ray Deschaies教授的思维火花碰撞带来了一个绝妙的想法，如果能给致病蛋白打上标签，将其送到用细胞内的天然“回收系统”进行“摧毁”，不就能达到治疗疾病的目的了吗？不仅如此，那些既往“难以成药”的靶点也将可以被干预。人类已知的与疾病有关的蛋白质中，超过90%还无法通过传统疗法靶向干预，仍需全新解决方案。 2001年，两位教授共同发表了一篇具有里程碑意义的论文，他们设计了一种分子，其一端是能够结合目标蛋白的小分子，另一端则是能结合E3连接酶的多肽。研究发现，这种人造分子的确能将目标蛋白“拉拽”到E3连接酶附近，利用泛素介导的蛋白降解系统进行降解。由于这是一款能够靶向蛋白进行降解的嵌合分子，Craig Crews教授将其命名为“PROTAC（PROteolysis TArgeting Chimera）”。在后续的研究中，Craig Crews教授团队又将PROTAC中的多肽部分替换为小分子，以提高细胞膜穿透能力、改善成药性。 为了更快推进PROTAC的研发，在2013年，Craig Crews教授创立了Arvinas公司。开发临床可用的PROTAC分子百端待举，首要任务便是解决口服疗法最关键的生物利用度问题。2016年，这一难关终获突破，挖掘更多候选PROTAC分子、加快启动临床前研究成为迫在眉睫的事项，Arvinas公司就选择了药明康德作为合作伙伴，8年来持续合作至今[参考资料1]。杨青博士介绍，“在PROTAC分子研发的多个环节，如化学研究、生物学研究、临床前实验、工艺开发和生产等，药明康德都提供了服务。”PROTAC技术从分子设计到纯化分析的一系列环节都充满挑战，但药明康德在早期就已经开始布局PROTAC相关能力和技术，能够完成PROTAC分子的发现、各种特殊结构和不同规模量级的定制化合成，以及分析纯化和测试，为PROTAC药物研发提供有力支持。 星光不负赶路人。2019年，首个PROTAC分子的论文发布后的18年，Arvinas公司的两款候选疗法首次挺进临床试验阶段，并于次年获得临床概念验证。2021年，Arvinas进一步公布积极数据，旗下靶向降解雌激素受体的ARV-471能够将患者肿瘤组织中的雌激素受体表达水平平均降低62%，这款分子也赢得了辉瑞高达20亿美元的合作，目前已处于临床3期研发阶段。另一款针对前列腺癌的在研疗法ARV-766在今年4月以高达10.1亿美元的数额授权诺华合作开发。此前，Arvinas公司的专有平台技术也赢得了基因泰克、拜耳等众多大型药企的青睐与合作。 在Arvinas公司率先斩获积极的临床数据后，整个蛋白降解疗法领域也迎来井喷式发展。2024年，已有近80款[参考资料9]在研蛋白降解疗法处于临床开发阶段。 从PROTAC到RIPTAC，创新永不止步 在PROTAC领域大获成功后，Craig Crews教授并未停下创新的脚步。 包括蛋白降解疗法在内的多种靶向抗癌疗法都基于相似的开发策略，那就是靶向癌症的驱动因子。但癌细胞会通过产生突变或者激活其它信号通路，不再依赖靶点蛋白的功能，从而产生耐药性。尽管如此，这些靶点蛋白仍然在癌细胞中特异性高度表达，能否进一步利用这些蛋白，开发新的抗癌疗法呢？ 这正是Craig Crews教授想到的全新策略——RIPTAC。与PROTAC类似，RIPTAC也利用了诱导接近的原理，其一端可结合肿瘤高表达的蛋白，而另一端与维持细胞生存的关键蛋白结合，它们构成的三元复合体会抑制细胞的生存功能，从而诱导肿瘤细胞死亡。健康细胞由于肿瘤特异性蛋白表达水平不高，所以不会形成复合体，也就不受影响。 Craig Crews教授也创立了一家全新的公司Halda Therapeutics来推进RIPTAC疗法开发。2023年2月，在美国临床肿瘤泌尿生殖学会（ASCO GU）癌症研讨会上，Halda公司首次公开展示了一款RIPTAC候选疗法的临床前数据，该疗法在小鼠模型中对于前列腺癌细胞生长的抑制作用优于当前的前列腺癌标准疗法。 这一开创性模式的潜力迅速得到行业的关注和认可。2024年8月，Halda公司宣布已完成1.26亿美元的B轮扩展融资，获得的资金将用于推动两款RIPTAC候选药物进入临床试验，其中一款药物HLD-0915预计将在2025年上半年启动针对转移性、去势抵抗性前列腺癌（mCRPC）患者的1期临床试验。 此前药明康德在蛋白降解疗法领域合作中展现出的高质量服务和成果交付实力也获得了合作伙伴的高度认可。Arvinas董事长、总裁兼首席执行官John Houston博士曾在一次公开访谈中赞赏道[参考资料2]：“如果没有这种合作关系，我们就不会走到今天的位置。”疾风知劲草，Halda公司在2019年成立之初即选择与药明康德再度携手，并在关键新药即将进入临床开发阶段时进一步扩大了与药明康德的合作范畴[参考资料1]。 CRDMO端到端赋能，加速学术成果转化落地 从实验室的基础研究成果到具有变革性的创新疗法，Craig Crews教授创立的两家公司赋予了小分子药物全新的定义。药明康德能够在这个领域发展初期就成为这两家新锐公司的合作伙伴也绝非偶然，这得益于独特的CRDMO业务模式。R（研究）让药明康德能够立于产业前沿，及时捕捉机遇并快速建设相应能力，同时R端还能够为下游D+M（开发+生产）业务开源和引流，并形成合力，打通新药研发全链条，实现“端到端”的助力。理解这些趋势并建立能力的过程也形成了强大的“飞轮效应”，使得药明康德能够在行业风口早期把握机遇，充分感知用户需求，并形成规模效应、快速迭代更新，最终为客户极致赋能，加快新药研发，造福患者。 多年来，药明康德针对蛋白降解疗法开发已搭建了完善的一体化赋能平台，服务超过150家客户，全球市场渗透率达66%。在其他多类新分子领域，药明康德也走在行业前列，新分子整体市场渗透率约26%。 我们期待Craig Crews教授的这两家公司走得更远，更快带来相应疗法问世，造福更广泛的患者。药明康德也将一如既往地站在行业前沿，为那些富有勇气的创新开拓先锋赋能，以期实现“让天下没有难做的药，难治的病”。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放 参考资料（可上下滑动查看） [1] 2024 WuXi AppTec Investor Day, Research Enabling Platforms Enhance CRDMO Model. Retrieved October 17, 2024 from https://static.wuxiapptec.com/99/20240926/2024%20WuXi%20AppTec%20Investor%20Day%20-%20Research%20Enabling%20Platforms.pdf [2] 降解无可成药性靶点，PROTAC距离新药研发圣杯还有多远？| 专访. Retrieved October 17, 2024 from https://mp.weixin.qq.com/s/MBvZ3dJh-tqVZ0y_a1qung [3] Arvinas. Retrieved October 1, 2024 from https://www.arvinas.com/research-and-development/pipeline/ [4] Arvinas Announces Oversubscribed $350 Million Private Placement. Retrieved November 27, 2023 from https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-oversubscribed-350-million-private-placement [5] Halda Therapeutics Secures $126 Million Financing to Advance RIPTAC™ Cancer Therapies into the Clinic for Major Solid Tumors. Retrieved August 12, 2024, from https://haldatx.com/halda-therapeutics-secures-126-million-financing-to-advance-riptac-cancer-therapies-into-the-clinic-for-major-solid-tumors [6] MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results. Retrieved August 12, 2024, from https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-50-million-offering-ordinary-shares-led [7] A tinkerer takes on cancer by hijacking the tiny garbage trucks inside every cell. Retrieved May 18, 2016 From https://www.statnews.com/2016/05/18/cancer-cellular-garbage-trucks/ [8] Békés, M., Langley, D.R. & Crews, C.M. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21, 181–200 (2022). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41573-021-00371-6 [9] Insight数据库 [10] Halda Therapeutics unveils its first pipeline data for RIPTAC™ therapeutics, a new drug modality, at ASCO GU Symposium. Retrieved February 14, 2023 from https://www.businesswire.com/news/home/20230214005390/en/Halda-Therapeutics-unveils-its-first-pipeline-data-for-RIPTAC%E2%84%A2-therapeutics-a-new-drug-modality-at-ASCO-GU-Symposium  [11] An Oral RIPTACTM Therapeutic for Prostate Cancer. Retrieved February 2023 from https://haldatx.com/wp-content/uploads/2023/02/ASCO-GU-Feb2023-Poster.pdf [12] Global Trends in R&D 2024. Retrieved February 2024 from https://aigc.idigital.com.cn/djyanbao/%E3%80%90IQVIA%E3%80%912024%E5%B9%B4%E5%85%A8%E7%90%83%E6%96%B0%E8%8D%AF%E7%A0%94%E5%8F%91%E8%B6%8B%E5%8A%BF-2024-03-31.pdf 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新